-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Product Insights
Overweight: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Overweight - Global Clinical Trials Review, 2025" provides an overview of Overweight Clinical trials scenario. This report provides top line data relating to the clinical trials on Overweight. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Amyloidosis - Global Clinical Trials Review, 2025" provides an overview of Amyloidosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyloidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Hyperglycemia - Global Clinical Trials Review, 2025" provides an overview of Hyperglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hypoglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Hypoglycemia - Global Clinical Trials Review, 2025" provides an overview of Hypoglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypoglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Phenylketonuria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Phenylketonuria Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Phenylketonuria in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - PKU is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The PKU pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Macular Edema - Global Clinical Trials Review, 2025" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diabetic Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Nephropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the obesity market through 2031. GlobalData estimates sales of obesity therapeutics to be approximately $10.5 billion across the 7MM in 2021. By 2031, GlobalData expects the obesity market to grow at a strong compound annual growth rate (CAGR) of 32.3%, reaching sales of $173.5 billion by the end of the forecast period. Major drivers of growth in the obesity market during...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.